Galectin (GALT) Reports Improved Financial Performance in Q3 2024
Galectin Therapeutics Inc. (GALT) is a pioneering biopharmaceutical company dedicated to developing innovative therapies that target galectin proteins,…
Health In Tech (HIT) Achieves $289.8M Market Cap with Robust Growth Potential
Health In Tech Inc. (HIT) is a leading innovator in the Insurtech industry, specializing in technology-driven solutions that…
Septerna (SEPN) Raises $302.6 Million in IPO to Fuel Drug Development Pipeline
Septerna Inc. (SEPN) is a clinical-stage biotechnology company revolutionizing drug discovery through its proprietary Native Complex Platform™, which…
BioLineRx (BLRX)’s APHEXDA Captures 10% Market Share in U.S. CXCR4 Inhibitors by Q3 2024
BioLineRx Ltd. (BLRX) is a cutting-edge biopharmaceutical company dedicated to developing and commercializing transformative therapies in oncology and…
Synergy (SNYR)’s Strategic Rebranding: A New Era for FOCUSfactor
Synergy CHC Corp. (SNYR) is a leading innovator in the consumer health and lifestyle products industry, delivering scientifically-backed…
Prostate Cancer Breakthrough: Candel Therapeutic (CADL)’s CAN-2409 Trials Near Completion
Candel Therapeutics Inc. (CADL) is a clinical-stage biopharmaceutical company dedicated to revolutionizing cancer treatment through advanced multimodal immunotherapies.…
Monopar Therapeutics (MNPR) Strengthens Financial Stability with $17.7M Public Offering
Monopar Therapeutics Inc. (MNPR) is a clinical-stage biotechnology company dedicated to transforming the treatment landscape for rare diseases…
Tectonic Therapeutic Reports Strong Q3 2024 Financial Results, $159.1M Cash Reserves
Tectonic Therapeutic Inc. (TECX) is a cutting-edge biotechnology company dedicated to pioneering advancements in the discovery and development…
Innoviva (INVA)’s Expanding Portfolio Drives 33% Revenue Growth in Q3 2024
Innoviva Inc. (INVA) is a forward-thinking healthcare company dedicated to advancing medical innovation and improving patient outcomes worldwide.…
Collegium (COLL) Reports $9.3M Net Income in Q3 2024 with Record-Breaking Product Sales
Collegium Pharmaceutical Inc. (COLL) is a trailblazer in the specialty pharmaceutical industry, dedicated to improving the lives of…
Arcutis (ARQT) Achieves $44.8M in Q3 2024 Revenue, Growing 452% Year-Over-Year
Arcutis Biotherapeutics Inc. (ARQT) is a commercial-stage biopharmaceutical company dedicated to revolutionizing the treatment of immune-mediated skin diseases.…
Amylyx (AMLX) Reports $234.4M in Cash, Secures Financial Stability Through 2026
Amylyx Pharmaceuticals Inc. (AMLX) is a cutting-edge biotechnology company dedicated to developing innovative therapies for neurodegenerative and metabolic…
MiMedx (MDXG) Reports $84M in Q3 2024 Sales, Showcasing Financial Growth
MiMedx Group Inc. (MDXG)’s a leading regenerative medicine company specializing in advanced wound care and placental tissue technologies.…
Cassava Sciences (SAVA) Secures $149M to Support Simufilam Trials Into 2026
Cassava Sciences Inc. (SAVA) is a clinical-stage biotechnology company at the forefront of advancing treatments for Alzheimer’s disease,…
Puma Biotechnology (PBYI) Reports $140.8M NERLYNX® Revenue in 2024 Amid Operational Excellence
Puma Biotechnology Inc. (PBYI) is a cutting-edge biopharmaceutical company dedicated to transforming cancer treatment through innovative therapies. Founded…
Lakeside Holding (LSH) Deepens Roots in Pharmaceutical Logistics with $1.5M Sinopharm Agreement
Lakeside Holding Limited (Nasdaq: LSH) has signed a $1.5 million sales agreement with Sinopharm Holding Hubei New Special…
NeuBase (NBSE)’s PATrOL™ Platform: The Future of RNA-Targeted Therapies
NeuBase Therapeutics Inc. (NBSE) is a biotechnology company at the forefront of genetic medicine, leveraging its proprietary PATrOL™…
Analysts Maintain Optimism as Lexicon Pharmaceuticals (LXRX) Focuses on Long-Term Growth
Lexicon Pharmaceuticals, Inc. (LXRX), founded in 1995 and headquartered in The Woodlands, Texas, is a clinical-stage biopharmaceutical company…